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Abstract 
This mini-review brings together information from publications and recent conference 
proceedings that have shed light on the biological interaction between 
transglutaminase-2 and heparan sulphate proteoglycans.  We subsequently draw 
hypothesis of possible implications in the wound healing process. There is a 
substantial overlap in the action of transglutaminase-2 and the heparan sulphate 
proteoglycan syndecan-4 in normal and abnormal wound repair. Our latest findings 
have identified syndecan-4 as a possible binding and signalling partner of fibronectin-
bound TG2 and support the idea that transglutaminase-2 and syndecan-4 acts in 
synergy. 
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 Role of transglutaminase-2 in wound healing: open questions on its 
externalisation. Transglutaminases catalyse the post-translation modification of 
proteins predominantly via crosslinking glutamine and lysine amino acids on adjacent 
polypeptides (Lorand and Graham 2003). These covalent ε-(γ-glutamyl) lysine 
crosslinks are stable and resistant to enzymatic, chemical and mechanical disruption 
(Lorand and Conrad 1984). Several transglutaminases have been characterised with 
distinct genes, structures and physiological functions (Lorand and Graham 2003). 
Examples include the plasma factor XIIIa involved in crosslinking fibrin during clot 
formation and the keratinocyte transglutaminase involved in the formation of the 
cornified envelope during terminal differentiation.  The tissue transglutaminase or 
transglutaminase-2 (TG2), the most widespread member of this family, is present in 
many different cell types and has been implicated into a plethora of biological 
functions (Fesus and Piacentini 2002; Griffin et al. 2002; Lorand and Graham 2003), 
among which the role of TG2 in the normal and abnormal wound healing response is 
well established in vitro and shown in vivo (Verderio et al. 2005). The predominant 
role of TG2 in a wound response seems to be in stabilising the cells’ extracellular 
environment, by affecting the extracellular matrix (ECM) composition and altering 
the cells’ adhesive and migration potential.  The chronic over expression and cellular 
secretion of TG2 has been observed in numerous scarring and fibrotic-like disease 
states which are the result of continuous insult and chronic repair. These include 
kidney fibrosis (Johnson et al. 2003; Johnson et al. 1997; Johnson et al. 1999), liver 
fibrosis (Grenard et al. 2001; Qiu et al. 2007), pulmonary fibrosis (Griffin et al. 1979; 
Richards et al. 1991), atherosclerosis (Sane et al. 2007), myocardial myopathy (Small 
et al. 1999) and nephrogenic systemic fibrosis (Parsons et al. 2007).  In experimental 
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renal scarring, the predominant role of TG2, once secreted by tubular epithelial cells 
or mesangial cells, is associated with accumulation of ECM, both indirectly via TG2-
mediated fibroblast adhesion and migration into the damaged area, and directly by the 
formation of ε(γ-glutamyl) lysine dipeptide bonds within the ECM (Verderio et al. 
2005).  TG2 crosslinking subsequently accelerates the rate of collagen deposition by 
non conventional pathways, while conferring the ECM with resistance to matrix 
metalloproteinase degradation (Fisher et al. 2005). 
 
In this process, it remains unclear how TG2 is exported from the cell and released into 
the extracellular environment and targeted to the cell surface and ECM, since TG2 
does not have a signal peptide and thus ER/Golgi dependent N-glycosylation can not 
occur (Gentile et al. 1991; Lorand and Graham 2003).  TG2 must therefore be 
trafficked by a non-classical secretion route.  Although a key trigger for TG2 export is 
cell stress, TG2 is not released non-specifically due to cell death/damage, since 
extracellular trafficking occurs in the absence of leakage of intracellular components 
and cells remain viable (Li et al. 2002; Skill et al. 2004). Once exported into the 
ECM, TG2 appears to have an additional non enzymatic structural adhesive role in 
reinforcing the integrin-fibronectin (FN) interaction in a way which is independent 
from the ArgGlyAsp “RGD” cell binding domain of fibronectin (Verderio et al. 
2003). However, while we know that TG2 can associate with integrin β1 and FN at 
the cell surface (Akimov et al. 2000), exactly how TG2 at these sites is controlled is 
unknown. We initially reported that TG2-mediated RGD-independent cell adhesion is 
based on its interaction with cell-surface heparan sulphate (HS) chains (Verderio et al. 
2003). In the course of the past few years, new observations have accumulated which 
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support the hypothesis that the biological role of TG2 may be modulated by its 
interaction with HS proteoglycans (HSPG)s.  
 
Possible role of heparan sulfates in mediating the biological action of TG2. 
HSPGs are specialised glycoproteins with a core protein linked to one or more HS 
glycosoaminoglycans (GAG) chains, which are linear polysaccharides consisting of 
alternating N-acetylated or N-sulphated glucosamine units, and uronic acids (Bishop 
et al. 2007). The assembly of HS chains on core proteins, which is catalysed by 
enzymes of the Golgi, leads to a wide structural heterogenicity (e.g. chain size and 
length, extent of sulphation, spatial distribution of negatively charged groups etc.). 
Bergamini and collegues have shown that TG2 has some affinity for the heparan-
sulfate analogue heparin, since a heparin-Sepharose column was used in the last step 
of purification of TG2 from erythrocytes (Signorini et al. 1988). They subsequently 
showed that binding of TG2 to heparin does not affect the catalytic activity of the 
enzyme but protect it from thermal unfolding and proteolytic degradation (Gambetti 
et al. 2005). Interestingly, adhesive ECM glycoproteins such as FN and vitronectin, 
and growth factors such as midkine, which all serve as substrates for TG2 
transamidation, are also heparin-binding proteins. In some cases, the TG2-mediated 
protein transamidation can be even augmented by GAGs such as heparin (Sane et al. 
1990), suggesting that heparin could help immobilise TG2 on these target substrates. 
 
In collaboration with Dr Lortat-Jacob (Institut de Biologie Structurale CNRS-CEA, 
Grenoble), we have recently studied the interaction of TG2 for HS using, for the first 
time, a physiologically relevant assay based on surface plasmon resonance (SPR). 
This assay demonstrated high affinity of recombinant human TG2 for heparin 
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(Scarpellini et al. 2007), suggesting the presence of heparin binding sites within TG2. 
The negative charge of HS chains makes them associate with high affinity to basic 
amino acids.  Work by Cardin and Weintraub (Cardin and Weintraub 1989) has led to 
the identification of heparin-binding consensus sequences, amongst which the 
putative heparin-binding motif XBBXB (B is a basic amino acids and X a hydropathic 
amino acid) can be found in human TG2 (261-65). This TG2 site appears to be 
accessible to HS chains, moreover it is conserved among different species (human, 
rat, mouse, guinea pig) (Figure 1). However, it seems s to be specific for TG2 since it 
is not conserved in human Tranglutaminase-1, -5, -7 and Factor XIIIa; the motif is 
also not conserved in Transglutaminase-3 and -6, however in this case it is replaced 
by basic amino acids which may have some affinity for HS (data not shown). Apart 
from the XBBXB motif described above, there are other candidate clusters rich in Lys 
and Arg which might function as possible HS binding sites, although the TG2 protein 
is relatively acidic overall, and based on the electrostatic surface there are no very 
obvious domains. 
 
Experiments with cells in culture have shown that heparitinase digestion of cell-
surface HS, but not digestion of choindrotin sulphates, impairs the RGD-independent 
cell spreading and actin assembly mediated by FN-bound TG2 (Verderio et al. 2003). 
However, digestion of HS did not significantly affect actin assembly mediated by FN 
(Verderio et al. 2008), consistent with previous reports showing that HS-deficient 
syndecan-4 core proteins are sufficient to support the formation of stress fibers 
(Echtermeyer et al. 1999). Hence, our findings suggest that cell-surface HS are 
essential to support TG2-mediated RGD-independent cell adhesion. 
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In summary, the affinity of TG2 for HS as demonstrated by (i) plasmon surface 
resonance,  (ii) the presence of at least one heparin binding motif in TG2 and (iii) the 
loss of TG2-mediated RGD-independent adhesion following HS digestion, gives 
strong support to the hypothesis of TG2 binding to cell-surface HSPGs receptors. 
 
Syndecan-4 is a candidate co-receptor for TG2. There are three main subclasses of 
HSPGs, which may all potentially interact with TG2 (Bishop et al. 2007). The HSPGs 
belonging to the Syndecan family of cell-surface receptors consist of a core protein 
embedded in the membrane lipid bilayer and glycoproteins extending into the 
extracellular environment. Syndecans typically function as receptors for signalling 
peptides such as fibroblasts growth factor (FGF), vascular endothelial growth factor 
(VEGF) and transforming growth factor-β (TGFβ).  Glypicans are HSPGs attached to 
the cell surface via a glycophosphatidyl-inositol (GPI) membrane anchor, and have a 
critical function in developmental morphogenesis (Filmus and Selleck 2001). 
Perlecans are among a class of secreted proteoglycans found in the basement 
membranes and are predominantly associated with generating a negatively charged 
membrane to modify membrane transport e.g. in the glomerular basement membrane 
(Bishop et al. 2007). 
 
Transgenic mice with a defect in the expression of the Syndecan family member 
Syndecan-4 and Syndecan-1 are healthy, fertile but present delayed wound healing 
(Echtermeyer et al. 2001; Stepp et al. 2002).  Syndecan-1 is principally involved into 
keratinocyte migration and re-epithelization, while syndecan-4 is important in 
fibroblasts migration. The viable phenotype may be due to the variety of HS present 
in cells which may compensate for the lack of Syndecan-1 or -4 at the cell surface. In 
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fact, targeted deletion in mice of N-acetylglucosamine N-deacetylase-N-
sulfotransferase (Ndst), the enzyme which catalyzes the first sulfation step in the 
synthesis of HS, has resulted into embryonic lethality (Fan et al. 2000). Among all the 
proposed functions, a key role of cell-surface HSPGs is that of regulating the activity 
of fibroblast growth factor 2 (FGF2), by facilitating the interaction of FGF-2 with its 
receptor through a low but important affinity with HS. This finding is supported by 
crystallographic structures of heparan sulfate associated with an FGF in complex with 
its receptor (Pellegrini et al. 2000). 
 
Among the subfamilies of HSPGs, a possible candidate receptor for TG2 in cell 
adhesion and migration is Syndecan 4 (S4), which is the only member of the 
Syndecan family to be consistently present in focal adhesions (Morgan et al. 2007). 
S4 acts as a co-receptor for both ECM components and soluble ligands (growth 
factors).  In response to an ECM ligand, the S4 cytoplasmic domain binds 
phosphatidylinositol 4,5, biphosphate and directly activates protein kinase Cα 
(PKCα) to promote cellular spreading (Oh et al. 1997).  Therefore, the binding of 
TG2 to S4 is consistent with the requirement of PKCα activity to support TG2-
mediated RGD-independent cell adhesion, demonstrated by the finding that a PKC 
inhibitor with high specificity for PKCα can block this adhesive pathway (Verderio et 
al. 2003). However, the signalling activity of S4 at focal adhesions is not exclusive for 
PKCα. It also leads to the activation of focal adhesion kinase (FAK), as demonstrated 
by the lower phosphorylation levels of FAK Tyr(397) in fibroblasts derived from 
syndecan-4-null mice allowed to adhere on FN for 3 hours,  and by the rescuing of 
FAK Tyr(397) phosphorylation by re-expression of syndecan-4 (Wilcox-Adelman et 
al. 2002). We have now confirmed that syndecan-4-null fibroblasts have a lower level 
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of FAK Tyr(397) also in the starting phase of cell adhesion to FN (40-minutes 
adhesion), compared to wild-type cells (Verderio et al. 2008). In this initial phase of 
adhesion, FAK is responsible for the early downregulation of the small GTPase 
RhoA, event which facilitates cell spreading and migration (Ren et al. 1999). 
Interestingly, we measured an analogue defect in early FAK Tyr(397) 
phosphorylation in TG2-null mouse embryonic fibroblasts, compared to wild type 
fibroblasts, which was accompanied by hyperactivation of RhoA and decreased cell 
migration (Verderio et al. 2008) . This similarity between the interference of S4 and 
TG2 function in early FAK activation, could be explained by the cooperation between 
TG2 and S4 at focal adhesion.  Indeed, recent work in our laboratories has 
demonstrated the association of S4 and TG2 in cell membranes of human osteoblasts 
(HOB), a cell type known to be rich in RGD-independent, HS-mediated adhesive 
pathways (Verderio et al. 2003), which could explain their convergence of action.  In 
this study, we have shown that TG2 is present in S4 immunoprecipitates of wild type 
and TG2-transfected human osteoblasts (HOB-TG14) (Verderio et al. 2001) and that 
pre-treatment of cells with heparitinase lowers the amount of co-immunoprecipitated 
TG2.  This however, is not decreased by pre-incubation of cells with competitive 
concentrations of a peptide that mimics the FN binding site within TG2 (Hang et al. 
2005), and thus inhibits TG2-FN binding (Scarpellini et al. 2007), suggesting a direct 
interaction of TG2 with S4.  We have also began demonstrating the S4-TG2 
association in cell membranes of stably transformed Swiss 3T3 cell lines, generated 
by transfecting TG2 cDNA under the control of a tetracycline-regulated inducible 
promoter (unpublished data). These findings collectively indicate that TG2 associates 
with the HS chains of S4 and that this interaction is direct and not mediated by 
heparin-binding FN. Furthermore, we have found that S4 is required to mediate the 
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adhesive action of matrix TG2, since S4-null dermal fibroblasts, originating from S4 
knockout mouse (Ishiguro et al. 2000), display a significantly lower level of RGD-
independent focal adhesion assembly and phosphorylation of FAK at Tyr397 
compared to wild type fibroblasts (Verderio et al. 2008). Work from Griffin and co-
workers have shown that not only S4, but also Syndecan-2 is a potential cell-surface 
receptor for TG2 in HOB (personal communication). 
 
Collectively, these findings demonstrate the direct association of TG2 with S4 and the 
dependence of TG2 on S4 in cell adhesion, supporting the hypothesis that S4 may 
function as a co-receptor for TG2.   
 
Do TG2 and Syndecan 4 interact in vivo? 
It is apparent that both TG2 and S4 are implicated in similar functions in cell-ECM 
interactions that are important for wound repair. In injured mice (skin wounding), S4 
is overexpressed in many cell types in the granulation tissue (Gallo et al. 1996). The 
activity of TG2 is also found to be significantly increased at day 1-3 post skin 
wounding in rat (Haroon et al. 1999). A role of S4 in wound healing is supported by 
the finding of delayed wound repair in S4-null mice, as previously discussed 
(Echtermeyer et al. 2001). Similarly, delayed wound healing was reported in TG2-null 
mice by R Graham and colleagues (Mearns et al. 2002). These defects in repair 
associated with S4 and TG2 deletion can be reproduced in vitro utilising a “wound 
scratch assay” with either S4-null fibroblasts originating from S4 knockout mouse 
(Echtermeyer et al. 2001) or TG2-null fibroblasts generated by antisense RNA 
(Stephens et al. 2004) or derived from TG2-knockout mouse (Verderio et al. 2008). 
TG2 and S4 both appear to be implicated in conditions of continuous insult leading to 
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tissue fibrosis e.g. kidney scarring. Chronic over-expression and cellular secretion of 
TG2 is a major contributing factor to the pathogenesis of kidney scarring (Johnson et 
al. 2007). An increase in total HSPGs was also found in the glomerulus and tubulo 
interstitium of renal biopsies of patients with renal disease (Morita et al. 1994). More 
specifically, the HSPG member S4 (Lorand and Conrad 1984) was found to be up-
regulated in IgA nephropathy (Yung et al. 2001) and diabetic nephropathy (Fan et al. 
2003). These functional similarities in vivo are consistent with the interaction of TG2 
and S4 that we have begun to demonstrate in vitro, and could possibly be explained 
by a synergistic action. However, to demonstrate whether TG2 and S4 interact in vivo, 
it is important to determine the dependence on each other for these roles. Our 
preliminary studies have shown a reduced level of fibrosis (quantified by Masson’s 
trichrome staining) in sections of kidney from S4-knockout mice subjected to 
experimental scarring induced by unilateral ureteric obstruction (UUO), compared to 
similarly treated wild type inbred C57BL/6J mice. The protection of kidney fibrosis 
caused by S4 deletion is consistent with its over-expression in fibrotic tissue (Morita 
et al. 1994), and is reminiscent to that seen in TG2 knockout mice (Mohammed et al. 
2006). Our further observation, that S4 deletion is associated with a significant 
reduction in extracellular TG activity in kidney sections of S4 knockout mice 
compared to WT mice post UUO, suggests that S4 and TG2 may cooperate in the 
repair process (Scarpellini, Johnson&Verderio, unpublished data). 
 
Perspectives 
A substantial body of new observations has confirmed the affinity of TG2 for HS, 
which is a common component of the ECM (Bishop et al. 2007), and has begun to 
define the physiological significance of the affinity of TG2 for HS chains.  As 
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discussed, we have identified the HS proteoglycan S4 as one possible co-receptor of 
TG2 on the cell surface of fibroblasts and osteoblasts (Scarpellini et al. 2008; 
Verderio et al. 2008). This finding forms the hypothesis of a possible cooperative 
action between TG2 and S4 in vivo, in normal and excessive repair processes. Given 
the known affinity of TG2 for integrin receptors (Akimov et al. 2000), and their 
synergistic action with S4, one avenue of research would be that of identifying the 
signalling pathways induced by TG2 engagement to both receptors.  Furthermore, the 
interaction of TG2 with the other members of HSPGs subfamilies remains to be 
investigated. Indeed, the wide range of HSPGs raises the possibility of different TG2-
HS proteoglycan combinations depending on cellular context. Furthermore, the great 
structural heterogeneicity of the HS chains with possible specialised function 
(Seeberger and Werz 2007) generates the question of whether TG2 binds selectively 
to a preferential structure.  Another challenge in the field would be that of defining the 
mechanism of functional cooperation between S4 and TG2.  Examples of mechanisms 
could include a possible role of HS in the localisation and cell surface trafficking of 
TG2.  Interestingly, one well-known binding partner of HS is the leaderless secreted 
protein FGF-2. A recent report by Zehe et al (Zehe et al. 2006),  has shown that cell-
surface HS are necessary to guarantee FGF-2 secretion and that they would probably 
contribute to secure FGF-2 translocation through the plasma membrane by acting as 
“molecular traps”.  In the light of these findings, it would be useful to establish the 
role of HSPGs in TG2 localisation and cell trafficking as they may be involved in the 
unconventional secretion process of TG2 through a yet to be discovered mechanism.  
Indeed, given the length and flexibility of the HS chain, e.g. HSPGs can bind distant 
ECM components and even act across cells by binding and localising ligands on 
adjacent cells (Bishop et al. 2007), the HS chains could contribute to increase the 
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local concentration of TG2 and consequently its biological activity, as hypothesised in 
Figure 2. The association of TG2 with integrin receptors at the cell surface was 
initially described by Belkin and co workers (Akimov et al. 2000). We have now 
shown its further association with S4, raising the possibility of TG2 contributing to 
cell adhesion, via binding to the S4 ectodomain.  Telci et al. (Telci et al. 2007) have 
recently presented that RGD-independent cell adhesion mediated by FN-bound TG2 
depends on integrin β1, as the process is impaired in β1-null fibroblasts and it is 
restored by β1 re-expression. The concomitant interaction of TG2 with S4 and 
integrin receptors may have implications for their cooperative signalling, that could be 
dependent on the receptors’ spatial localisation.   
 
In conclusion, increased knowledge of TG2-HSPG interaction may contribute to 
answer open questions on TG2 localisation and trafficking and help design novel 
strategies for the specific inhibition of TG2 action, with important applications in 
early intervention against tissue scarring and fibrosis. 
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Figure Legends 
 
Figure 1.  
 
Multiple sequence alignment Allignment (ClustalW) of rat, mouse human and guinea 
pig liver Transglutaminase 2, showing a conserved putative heparin binding site based 
on the motif XBBXB (Cardin and Weintraub 1989), where B is either Arg (R) or Lys 
(K) and X an hydropathic amino acid. 
 
Figure 2. 
Hypothesis of Transglutaminase-2 (TG2) and HSPG (S4) interactions in the 
extracellular environment. The long and flexible HS chain with high TG2 affinity 
suggest HSPGs could bind either free TG2 in the extracellular space or assist in the 
cells own export of TG2 (1).  Alternatively HSPGs could act across cells by binding 
and localising TG2 on adjacent cells and “sequestering” TG2 from TG2 rich cells thus 
increasing the local concentration and biological activity of TG2 (2). For example in 
renal scarring infiltrating fibroblasts expressing S4 could obtain TG2 from tubular 
epithelial cells.  Cell surface bound TG2 could then have a role in both ECM 
deposition and stabilisation by intra-molecular crosslinking (Fisher et al. 2005; Skill 
et al. 2004) (3).   Cell surface TG2 could also interact with both integrin and cell-
surface HSPG (S4) and influence their spatial distribution, synergistic signalling as 
well as cell adhesion (4).  
 


